Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
Trial status:Recruiting
Study Identifier:
BNT327-01
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruiting
Trial details
Medical Condition
Study Drug
See more
Phase
Phase 2
Sex
Female & Male
Age
18+
Estimated Trial Date
Aug 2024 - Jan 2025
Protocol summary
This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) progressed on first- or second-line treatment (Cohort 2 and Cohort 3).
Trial locations
Location
Status
Location
Valkyrie Clinical Trials
Los Angeles, California, United States, 90067
Status
Recruiting
Location
Clermont Oncology Center
Clermont, Florida, United States, 34711
Status
Recruiting
Location
Fort Wayne Medical Oncology and Hematology, Inc
Fort Wayne, Indiana, United States, 46804
Status
Recruiting
Location
Clinical Research Alliance Inc
Westbury, New York, United States, 11590
Status
Recruiting
Location
University of Tennessee Medical Center
Knoxville, Tennessee, United States, 37920
Status
Not yet recruiting
Location
North Devon District Hospital - Northern Devon Healthcare NHS Trust
Barnstaple, United Kingdom, ES31 4JB
Status
Not yet recruiting